1.Balloon Aortic Valvuloplasty for a High-Risk Patient Using Percutaneous Cardiopulmonary Support
Kunihiko Yoshino ; Kohei Abe ; Yusuke Nakanishi ; Joji Ito ; Hiroyasu Misumi
Japanese Journal of Cardiovascular Surgery 2016;45(2):76-79
Balloon aortic valvuloplasty (BAV) is a treatment for high risk patients with severe aortic valve stenosis (AS). Rapid pacing is needed to reduce cardiac output when dilating the balloon, but it may cause cardiac ischemia or lethal arrhythmia. In this case report, percutaneous cardiopulmonary support (PCPS) was used to prevent these complications with BAV. We achieved adequate blood pressure and cardiac output during BAV without using rapid pacing by drawing a certain amount of blood into the reservoir equipped with the PCPS circuit. When performing BAV, PCPS may be a useful option for the patients who have high risks of circulatory failure.
3.Salicylamide Enhances Melanin Synthesis in B16F1 Melanoma Cells
Biomolecules & Therapeutics 2021;29(4):445-451
Salicylamide, a non-steroidal anti-inflammatory drug (NSAID), is used as an analgesic and antipyretic agent. We have previously shown that several NSAIDs have anti-melanogenic properties in B16F1 melanoma cells. In contrast, we have found that salicylamide enhances melanin contents in B16F1 melanoma cells; however, the underlying mechanism is not known. Therefore, we investigated the mechanism through which salicylamide stimulates melanogenesis. Interestingly, salicylamide enhanced diphenolase activity in a cell-free assay. Western blotting and real-time RT-PCR revealed that salicylamide increased tyrosinase expression via transcriptional activation of the Mitf gene. Together, our results indicate that salicylamide could be used as an antihypopigmentation agent for skin and/or hair.
4.Salicylamide Enhances Melanin Synthesis in B16F1 Melanoma Cells
Biomolecules & Therapeutics 2021;29(4):445-451
Salicylamide, a non-steroidal anti-inflammatory drug (NSAID), is used as an analgesic and antipyretic agent. We have previously shown that several NSAIDs have anti-melanogenic properties in B16F1 melanoma cells. In contrast, we have found that salicylamide enhances melanin contents in B16F1 melanoma cells; however, the underlying mechanism is not known. Therefore, we investigated the mechanism through which salicylamide stimulates melanogenesis. Interestingly, salicylamide enhanced diphenolase activity in a cell-free assay. Western blotting and real-time RT-PCR revealed that salicylamide increased tyrosinase expression via transcriptional activation of the Mitf gene. Together, our results indicate that salicylamide could be used as an antihypopigmentation agent for skin and/or hair.
5.The Current Strategy for Managing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.
Yusuke NIINA ; Nao FUJIMORI ; Taichi NAKAMURA ; Hisato IGARASHI ; Takamasa OONO ; Kazuhiko NAKAMURA ; Masaki KATO ; Robert T JENSEN ; Tetsuhide ITO ; Ryoichi TAKAYANAGI
Gut and Liver 2012;6(3):287-294
Multiple endocrine neoplasia type 1 (MEN1) is an inherited autosomal dominant disease presenting with pancreatic neuroendocrine tumors (pNETs), parathyroid tumors, or pituitary tumors. Using the PubMed database, we reviewed the literature on information regarding the proper diagnosis and treatment of MEN1-associated pNET. Many cases of MEN1-associated pNET are functioning pNETs. Gastrinomas and insulinomas tend to occur frequently in the duodenum and pancreas, respectively. In addition to diagnostic imaging, the selective arterial secretagogue injection test (SASI test) is useful for localizing functioning pNET. The standard treatment is surgical resection. However, in the case of a functioning pNET, the tumor should first be accurately located using the SASI test before an appropriate surgical method is selected. In cases of a MEN1-associated non-functioning pNET that exceeds 2 cm in diameter, the incidence of distant metastasis is significantly increased, and surgery is recommended. In cases of unresectable pNET, a somatostatin analog has been shown to demonstrate antitumor effects and is considered to be a promising treatment. In addition, molecular-targeted drugs have recently been found to be effective in phase III clinical trials.
Diagnostic Imaging
;
Duodenum
;
Gastrinoma
;
Incidence
;
Insulinoma
;
Multiple Endocrine Neoplasia
;
Multiple Endocrine Neoplasia Type 1
;
Neoplasm Metastasis
;
Neuroectodermal Tumors, Primitive
;
Neuroendocrine Tumors
;
Pancreas
;
Pituitary Neoplasms
;
Somatostatin
6.Quadricuspid Aortic Valve Complicated with Severe Aortic Regurgitation and Left-Sided Inferior Vena Cava.
Jun SHIRAISHI ; Kazunari OKAWA ; Kohei MUGURUMA ; Daisuke ITO ; Masayoshi KIMURA ; Eigo KISHITA ; Yusuke NAKAGAWA ; Masayuki HYOGO ; Akiyuki TAKAHASHI ; Takahisa SAWADA
Journal of Cardiovascular Ultrasound 2017;25(1):34-37
No abstract available.
Aortic Valve Insufficiency*
;
Aortic Valve*
;
Echocardiography, Transesophageal
;
Vena Cava, Inferior*
7.Establishment of a canine mammary gland tumor cell line and characterization of its miRNA expression.
Tomohiro OSAKI ; Yuji SUNDEN ; Akihiko SUGIYAMA ; Kazuo AZUMA ; Yusuke MURAHATA ; Takeshi TSUKA ; Norihiko ITO ; Tomohiro IMAGAWA ; Yoshiharu OKAMOTO
Journal of Veterinary Science 2016;17(3):385-390
Canine mammary gland tumors (CMGTs), which are the most common neoplasms in sexually intact female dogs, have been suggested as a model for studying human breast cancer because of several similarities, including relative age of onset, risk factors, incidence, histological and molecular features, biological behavior, metastatic pattern, and responses to therapy. In the present study, we established a new cell line, the SNP cell line, from a CMGT. A tumor formed in each NOD.CB17-Prkdc (scid)/J mouse at the site of subcutaneous SNP cell injection. SNP cells are characterized by proliferation in a tubulopapillary pattern and are vimentin positive. Moreover, we examined miRNA expression in the cultured cells and found that the expression values of miRNA-143 and miRNA-138a showed the greatest increase and decrease, respectively, of all miRNAs observed, indicating that these miRNAs might play a significant role in the malignancy of SNP cells. Overall, the results of this study indicate that SNP cells might serve as a model for future genetic analysis and clinical treatments of human breast tumors.
Age of Onset
;
Animals
;
Breast Neoplasms
;
Cell Line
;
Cell Line, Tumor*
;
Cells, Cultured
;
Dogs
;
Female
;
Humans
;
Incidence
;
Mammary Glands, Human*
;
Mice
;
MicroRNAs*
;
Risk Factors
;
Vimentin
8.Unilateral rostral mandibulectomy for gingival vascular hamartoma in two calves
Takeshi TSUKA ; Yoshiharu OKAMOTO ; Naoki YAMAMOTO ; Keiji HAYASHI ; Takehito MORITA ; Yuji SUNDEN ; Yusuke MURAHATA ; Kazuo AZUMA ; Tomohiro OSAKI ; Norihiko ITO ; Tomohiro IMAGAWA
Journal of Veterinary Science 2018;19(4):582-584
A 2-month-old female Holstein calf and a 5-month-old female Japanese black calf presented with gingival vascular hamartoma located in the interdental space between the second and third mandibular incisors in the right and left mandibles, respectively. On radiographic or computed tomographic images, osteolytic changes appeared within the mandibular bones adjacent to the masses. The masses were removed along with affected mandibular bone by using unilateral rostral mandibulectomy. After surgery, both cases exhibited a normal appetite and grew normally, with no cosmetic changes or recurrences. Unilateral rostral mandibulectomy can be applied for invasive gingival vascular hamartomas associated with osteolytic changes.
Animals
;
Appetite
;
Asian Continental Ancestry Group
;
Cattle
;
Female
;
Hamartoma
;
Humans
;
Incisor
;
Infant
;
Mandible
;
Mandibular Osteotomy
;
Radiography
;
Recurrence
9.Are Newer Extracorporeal Shock Wave Lithotripsy Models Truly Improving Pancreatolithiasis Lithotripsy Performance? A Japanese Single-Center Study Using Endoscopic Adjunctive Treatment
Ken ITO ; Naoki OKANO ; Kensuke TAKUMA ; Susumu IWASAKI ; Koji WATANABE ; Yusuke KIMURA ; Yuto YAMADA ; Kensuke YOSHIMOTO ; Seiichi HARA ; Yui KISHIMOTO ; Takahisa MATSUDA ; Yoshinori IGARASHI
Gut and Liver 2023;17(4):647-658
Background/Aims:
Many Japanese institutions use electromagnetic extracorporeal shock wave lithotripsy (ESWL) systems for treating pancreatic duct stones. However, there are no reports on direct comparisons between recent electromagnetic lithotripters. This study aimed to verify whether the new electromagnetic lithotripter can improve the efficiency of pancreatic stone fragmentation, and to clarify the role of combined endoscopic treatment on the clearance of pancreatic duct stones.
Methods:
We retrospectively identified 208 patients with pancreatolithiasis who underwent endoscopic adjunctive treatment after pancreatic ESWL at a single Japanese center over a 17-year period. We evaluated the outcome data of this procedure performed with SLX-F2 (last 2 years; group A) and Lithostar/Lithoskop (first 15 years; group B), as well as additional endoscopic treatments for pancreatolithiasis. We also performed logistic regression analysis to detect various factors associated with the procedure.
Results:
For pancreatic head stones, ESWL disintegration was achieved in 93.7% of group A patients and 69.0% of group B patients (p=0.004), and adjunctive endoscopic treatment removed stones in 96.8% of group A patients and 73.0% of group B patients (p=0.003). Multivariate analysis revealed that lithotripter type (odds ratio, 6.99; 95% confidence interval, 1.56 to 31.33; p<0.01) and main pancreatic duct stricture (odds ratio, 2.87; 95% confidence interval, 1.27 to 6.45; p<0.01) were significant factors for ESWL fragmentation.
Conclusions
The SLX F2 showed high performance in fragmenting the pancreatic duct stones.In addition, endoscopic adjunctive treatment improved the overall success rate of the procedure. The improved ESWL lithotripter has many advantages for patients undergoing pancreatic lithotripsy treatment.
10.Peroral pancreatoscopy with videoscopy and narrow-band imaging in intraductal papillary mucinous neoplasms with dilatation of the main pancreatic duct
Yui KISHIMOTO ; Naoki OKANO ; Ken ITO ; Kensuke TAKUMA ; Seiichi HARA ; Susumu IWASAKI ; Kensuke YOSHIMOTO ; Yuto YAMADA ; Koji WATANABE ; Yusuke KIMURA ; Hiroki NAKAGAWA ; Yoshinori IGARASHI
Clinical Endoscopy 2023;56(2):261-261